Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17328387 | 0.83 | MTNR1A (0.49) | METAP2MTNR1A | |
| SCHEMBL15374599 | 0.79 | METAP2 (1.00) | METAP2 | |
| SCHEMBL15374603 | 0.79 | METAP2 (1.00) | METAP2 | |
| SCHEMBL15375067 | 0.78 | METAP2 (0.72) | METAP2 | |
| SCHEMBL15375081 | 0.78 | METAP2 (1.00) | METAP2 | |
| SCHEMBL15375080 | 0.78 | METAP2 (1.00) | METAP2 | |
| SCHEMBL15375105 | 0.78 | METAP2 (0.76) | METAP2 | |
| SCHEMBL15374600 | 0.77 | METAP2 (0.71) | METAP2 | |
| SCHEMBL15374470 | 0.77 | METAP2 (0.82) | METAP2 | |
| SCHEMBL15374605 | 0.77 | METAP2 (0.74) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627631-B1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-8895535-B2 | Pyrrolidinones as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20130296274-A1 | PYRROLIDINONES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296274-A1 | PYRROLIDINONES AS METAP-2 INHIBITORS | METAP1, METAP2, DNPEP | METAP2 2/4885MTNR1A 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.